Pluri(NASDAQ) PLUR

Market Cap$12.78MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)-100%
5 Year-95%
1 Year-78%
1 Month-24%
$1.00
-3.38%
-0.04Today
Pluri last closing stock price
MetricPriceDate
Last closeUSD 1.042026-10-05
Pluri stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+6.7%USD 0.972026-09-28
1 month-23.9%USD 1.362026-09-04
3 month-50%USD 2.072026-07-07
Year to date-65.38%USD 2.992025-12-31
1 year-77.56%USD 4.612025-10-03
3 year-76.35%USD 4.382023-10-06
5 year-94.85%USD 20.082021-10-06
Since inception-99.94%USD 1,600.002003-04-16

Pluri Financials at a Glance

Market Cap

$12.78MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.02

Net Income (TTM)

-$25.37

EPS (TTM)

-$2.45

P/E Ratio

-0.42

Dividend

$0.00

Beta (Volatility)

0.85 (Low)

Price

$1.00

Volume

4,916.026

Open

$1.05

Previous Close

$1.04

Daily Range

$0.98 - $1.07

52-Week Range

$0.90 - $4.87

Estimated Earnings Date

N/A

PLUR News

557 doctor visit

Are Stem Cells the COVID-19 Treatment We've All Been Waiting For?

Maxx ChatskoApr 28, 2020
multiple lines up

Here's Why Pluristem Therapeutics Jumped Over 28% Today

Maxx ChatskoApr 24, 2020

Top Stories in Biotech This Morning: Pluristem Therapeutics, Inc, Rigel Pharmaceuticals, Inc. and Sangamo Biosciences, Inc.

George Budwell, PhDMar 6, 2014

Why Sinovac, Pluristem, and Synta Could Be Worth Watching Today

Leo SunNov 13, 2013

Why Pluristem Therapeutics Is Poised to Plunge

BRIAN PACAMPARAJan 16, 2013

3 Horrendous Health-Care Stocks This Week

Keith SpeightsDec 29, 2012

Are Short-Sellers Onto Something at Pluristem Therapeutics?

Rich DupreyNov 29, 2012

This Week in Biotech: Part 2

Sean WilliamsNov 10, 2012
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Pluri

Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.

Industry

Biotechnology

Sector

Health Care

Employees

92

CEO

Yaky Yanay, CPA

Website

www.pluri-biotech.com

PLUR Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-2.38%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$12.78MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

12.34M

Volume

4.92K

Avg. Volume

31.31K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Pluri Performance Analysis

Pluri annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30USD 287,00022.6%
20242024-06-30USD 326,00013.6%
20252025-06-30USD 1,336,000309.8%
20262026-06-30USD 1,016,000-24.0%
Pluri annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30USD -6.18-39.7%
20242024-06-30USD -3.99-35.5%
20252025-06-30USD -3.56-10.6%
20262026-06-30USD -2.44-31.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.34

+0.8%

Gross Profit

$0.07

+0.7%

Gross Margin

21.49%

+0.9%

Market Cap

$12.78MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$0.25

N/A

Employees

92

N/A

Net Income

-$6.19

+0.8%

EBITDA

-$5.42

+0.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$38.47

-4.7%

Total Debt

$34.91

+1.0%

Accounts Receivable

$0.09

+0.3%

Inventory

$0.00

N/A

Long Term Debt

$6.49

+1.1%

Short Term Debt

$28.43

+1.0%

Return on Assets

-74.95%

+1.3%

Return on Invested Capital

556.27%

-8.6%

Free Cash Flow

-$4.47

+0.8%

Operating Cash Flow

-$4.44

+0.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,777.74+0.01%
^DJIDJI
$51,304.21+0.00%
^IXICNASDAQ
$27,461.27+0.01%
BTCBitcoin
$85,510.00+0.00%

Questions About PLUR

What is the current price of Pluri?

Pluri is trading at $1.00 per share.

What is the 52-week range for Pluri?

Over the past 52 weeks, Pluri has traded between $0.90 and $4.87.

How much debt does Pluri have?

As of the most recent reporting period, Pluri reported total debt of $34.91M.

How much cash does Pluri have on hand?

Pluri reported $3.56M in cash and cash equivalents in its most recent financial results.

What is Pluri’s dividend yield?

Pluri does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services